Why the study?
Daily bleeding risk is highest during the first months after PCI for NSTE-ACS, and it remains unclear whether aspirin can be omitted immediately following the procedure.
Does omitting aspirin immediately following PCI for NSTE-ACS reduce bleeding without increasing ischemic events compared to 12 months of DAPT?
Does omitting aspirin immediately following PCI for NSTE-ACS reduce bleeding without increasing ischemic events compared to 12 months of DAPT?
The LEGACY study is designed to determine if omitting aspirin immediately after PCI for NSTE-ACS reduces bleeding without increasing ischemic risk compared to standard 12-month DAPT.
Answers are grounded in this paper and cite their sources.
LEGACY RCT will test immediate aspirin omission post-PCI in NSTE-ACS; extends DAPT de-escalation evidence to this high-bleeding-risk population.
Still the average daily bleeding risk is highest during the first months and it remains unclear if aspirin can be omitted immediately following PCI. Patients are randomized immediately following successful PCI for NSTE-ACS to 75-100 mg aspirin once daily versus no aspirin. The primary hypothesis is that immediately omitting aspirin is superior to DAPT with respect to major or minor bleeding defined as Bleeding Academic Research Consortium type 2, 3, or 5 bleeding, while maintaining noninferiority for the composite of all-cause mortality, myocardial infarction and stroke compared to DAPT. CONCLUSIONS: -inhibitor monotherapy, as compared to DAPT for 12 months on bleeding and ischemic events within 12 months following PCI for NSTE-ACS.
No takes yet. Share an insight, caveat, or question.
Sangen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: